Citius Pharmaceuticals Inc. is realigning its management team to strengthen its commercial capabilities, the Cranford biopharmaceutical company announced April 13. The company’s board of directors ...

Kytes positions itself as a project management software built for pharmaceutical realities—not generic project tracking. It supports regulatory execution, dossier readiness, country-wise launch ...

Royalty Pharma plc announced that its shareholders overwhelmingly approved the acquisition of its external manager, achieving 99.9% support during the 2025 Annual General Meeting. This transition to ...

Washington D.C. – June 17, 2014 – Specialty pharmaceutical management consulting firm Viscadia Inc. is pleased to announce the addition of Brandon Kocher Ph.D. to their team as an associate consultant ...

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management ...

LAS VEGAS--(BUSINESS WIRE)--Regenerex Pharma, Inc. (OTC: RGPX), announces the establishment of its comprehensive management team and the commencement of the Company manufacturing plans in Q4 2023.

MALMÖ, SE / ACCESS Newswire / November 3, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks ...

Dublin, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Waste Management Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The Pharmaceutical ...

Medical professional network Doximity (NYSE:DOCS) reported Q4 CY2025 results , with sales up 9.8% year on year to $185.1 ...

The reported sale lowered Arrowhead Pharmaceuticals to 2.94% of Privium's 13F reportable AUM as of September 30, 2025. Top holdings after the filing: TSLA: $108.51 million (19.5% of AUM) as of ...